Wajchenberg Bernardo Léo, Feitosa Alina Coutinho Rodrigues, Rassi Nelson, Lerário Antonio Carlos, Betti Roberto Tadeu Barcelos
Diabetes and Heart Center, Heart Institute, Hospital das Clinicas of the University of São Paulo Medical School, São Paulo, SP, Brazil.
Endocr Pract. 2008 Oct;14(7):912-23. doi: 10.4158/EP.14.7.912.
To evaluate the role of glycemic control in the development of cardiovascular disease (CVD) in type 1 diabetes mellitus (DM).
We review the literature regarding coronary atherosclerosis, coronary artery calcification, and the epidemiologic studies related to the role of glycemia and the classic risk factors for coronary artery disease (CAD) in type 1 DM.
Four prospective studies (Wisconsin Epidemiologic Study of Diabetic Retinopathy, EURODIAB, Steno Diabetes Center Study of Adults With Type 1 DM, and Pittsburgh Epidemiology of Diabetes Complications study) do not show that glycemic control predicts CAD occurrence. Findings from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study show that compared with conventional insulin therapy, intensive insulin therapy reduces CVD among patients with type 1 DM and is associated with lower prevalence of coronary artery calcification. The discrepancies between the findings from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study and the Pittsburgh Epidemiology of Diabetes Complication study are likely due to differences between the study populations and the lower prevalence of renal disease in the former study. Besides duration of DM and albuminuria/overt nephropathy, insulin resistance is a major determinant of CAD associated with type 1 DM.
Discrepant study results regarding the relationship between glycemia and CAD/coronary artery calcification may be related to the prevalence of renal disease and the presence of the metabolic syndrome. Published data suggest that addressing traditional risk factors including albuminuria, the metabolic syndrome, and inflammatory markers is better for preventing and treating CAD than focusing exclusively on glycemic control, which is still necessary for preventing microvascular complications. Furthermore, there is a synergistic effect of glycemic control and albuminuria on the development of CVD.
评估血糖控制在1型糖尿病(DM)心血管疾病(CVD)发生发展中的作用。
我们回顾了有关冠状动脉粥样硬化、冠状动脉钙化以及血糖作用和1型糖尿病中冠状动脉疾病(CAD)经典危险因素的流行病学研究文献。
四项前瞻性研究(威斯康星糖尿病视网膜病变流行病学研究、欧洲糖尿病研究、斯滕诺糖尿病中心1型糖尿病成人研究以及匹兹堡糖尿病并发症流行病学研究)未显示血糖控制可预测CAD的发生。糖尿病控制与并发症试验/糖尿病干预与并发症流行病学研究结果表明,与传统胰岛素治疗相比,强化胰岛素治疗可降低1型糖尿病患者的CVD发生率,并与冠状动脉钙化患病率较低相关。糖尿病控制与并发症试验/糖尿病干预与并发症流行病学研究和匹兹堡糖尿病并发症流行病学研究结果之间的差异可能是由于研究人群不同以及前者研究中肾病患病率较低。除了糖尿病病程和蛋白尿/显性肾病外,胰岛素抵抗是与1型糖尿病相关的CAD的主要决定因素。
关于血糖与CAD/冠状动脉钙化之间关系的研究结果存在差异,可能与肾病患病率和代谢综合征的存在有关。已发表的数据表明,解决包括蛋白尿、代谢综合征和炎症标志物在内的传统危险因素比单纯关注血糖控制更有利于预防和治疗CAD,而血糖控制对于预防微血管并发症仍然是必要的。此外,血糖控制和蛋白尿在CVD发生发展中具有协同作用。